Year Established: 1781
Revenues: $15,967 (+2%)
Net Income: $1,684 (+62%)
R&D: $2,935 (+4%)
TOP SELLING DRUGS
|Entyvio||ulcerative colitis, Crohn’s disease||$2,428||34%|
|Leuprorelin||prostate cancer, breast cancer, endometriosis||$790||-1%|
The largest, and only mega-deal of 2018 was Takeda’s $62 billion acquisition of Dublin, Ireland-based Shire. The deal, announced in May and finalized in January 2019, propels Takeda into the top 10 pharma companies and is one of the largest overseas acquisition deals ever in Japanese history. Projected sales for 2019 are in the $30 billion range.
With the Japanese pharma market lagging, Takeda’s purchase gives it an expanded geographic footprint, scale, and most importantly, a bigger foothold in the U.S. To offset pricing pressures in the U.S., the deal bolsters Takeda’s portfolio of rare disease therapeutics, currently viewed as an under-saturated market of high value due to regulatory incentives and high drug prices.
In addition to creating leading positions in rare diseases and plasma-derived therapies, complementing strengths in oncology and vaccines, the deal bolsters its portfolios in gastroenterology and neuroscience as well.
While the Shire deal was being worked out, in September Takeda unveiled plans to move its U.S. headquarters and 1,000 employees from the suburbs of Chicago to the Boston area, where most of Shire’s operations existed—3,000 of its employees in Lexington and Cambridge. The Japanese pharma giant is now the largest biopharma firm in the Boston area, which has overtaken rival California as the number one biotech hub in the world.
Takeda continued to diversify its cancer research activities with collaborations in immuno-oncology, an area of key strategic focus for the company. An alliance with Memorial Sloan Kettering aims to discover and develop novel CAR-T products for multiple myeloma, acute myeloid leukemia and solid tumor indications.
It also exercised an option under a research collaboration with Noile-Immune Biotech, licensing NIB-102 and NIB-103 for the treatment of various solid tumor indications, and will co-develop these CAR-T cell therapies with Noile using their “Prime” CAR-T platform. The company plans to gain regulatory approval for human testing of NIB-102 by the end of this year.
Through collaboration with external partners and the newly established translational cell therapy engine, Takeda is laying the foundation to deliver a rich pipeline of early-stage assets in the coming years.